Evidence map›Paper›PMID 33833585›Full record

ReviewHIV/AIDS (Auckland, N.Z.)2021

SARS-CoV-2 and Human Immunodeficiency Virus: Pathogen Pincer Attack.

Nicholas Evans, Edgar Martinez, Nicola Petrosillo, Jacob Nichols, Ebtesam Islam, Kevin Pruitt, Sharilyn Almodovar

Open access · goldAbstract readReview
In one paragraph

Review in HIV/AIDS (Auckland, N.Z.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Stability analysis of within-host SARS-CoV-2/HIV coinfection model.Mathematical methods in the applied sciences · 2022
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Nicholas EvansTexas Tech University Health Sciences Center, Department of Immunology & Molecular Microbiology, Lubbock, TX, USA.ORCID 0000-0002-9576-4454
Edgar MartinezTexas Tech University Health Sciences Center, Department of Immunology & Molecular Microbiology, Lubbock, TX, USA.
Nicola PetrosilloNational Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.ORCID 0000-0002-2585-7567
Jacob NicholsTexas Tech University Health Sciences Center, Department of Internal Medicine, Lubbock, TX, USA.
Ebtesam IslamTexas Tech University Health Sciences Center, Department of Internal Medicine, Lubbock, TX, USA.
Kevin PruittTexas Tech University Health Sciences Center, Department of Immunology & Molecular Microbiology, Lubbock, TX, USA.
Sharilyn AlmodovarTexas Tech University Health Sciences Center, Department of Immunology & Molecular Microbiology, Lubbock, TX, USA.
Texas Tech University · USIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paramount efforts worldwide are seeking to increase understanding of the basic virology of SARS-CoV-2, characterize the spectrum of complications associated with COVID-19, and develop vaccines that can protect from new and recurrent infections with SARS-CoV-2. While we continue learning about this new virus, it is clear that 1) the virus is spread via the respiratory route, primarily by droplets and contact with contaminated surfaces and fomites, as well as by aerosol formation during invasive respiratory procedures; 2) the airborne route is still controversial; and 3) that those infected can spread the virus without necessarily developing COVID-19 (ie, asymptomatic). With the number of SARS-CoV-2 infections increasing globally, the possibility of co-infections and/or co-morbidities is becoming more concerning. Co-infection with Human Immunodeficiency Virus (HIV) is one such example of polyparasitism of interest. This military-themed comparative review of SARS-CoV-2 and HIV details their virology and describes them figuratively as separate enemy armies. HIV, an old enemy dug into trenches in individuals already infected, and SARS-CoV-2 the new army, attempting to attack and capture territories, tissues and organs, in order to provide resources for their expansion. This analogy serves to aid in discussion of three main areas of focus and draw attention to how these viruses may cooperate to gain the upper hand in securing a host. Here we compare their target, the key receptors found on those tissues, viral lifecycles and tactics for immune response surveillance. The last focus is on the immune response to infection, addressing similarities in cytokines released. While the majority of HIV cases can be successfully managed with antiretroviral therapy nowadays, treatments for SARS-CoV-2 are still undergoing research given the novelty of this army.

Indexed as

ACE-2AIDSCOVID-19HIVremdesivirSARS-CoV-2

Identifiers

PMID33833585
PMCPMC8020331
OpenAlexW3152077509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.